Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Halozyme Therapeutics Inc shares valued at $1,148,618 were sold by Torley Helen on Jul 10 ’25. At $57.43 per share, Torley Helen sold 20,000 shares. The insider’s holdings dropped to 733,719 shares worth approximately $42.56 million following the completion of this transaction.
Also, Torley Helen sold 20,000 shares, netting a total of over 1,128,655 in proceeds. Following the sale of shares at $56.43 each, the insider now holds 733,719 shares.
Before that, Torley Helen had sold 20,000 shares from its account. In a trade valued at $1,110,245, the PRESIDENT AND CEO traded Halozyme Therapeutics Inc shares for $55.51 each. Upon closing the transaction, the insider’s holdings decreased to 20,000 shares, worth approximately $42.56 million.
Analysts at Morgan Stanley downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal-weight”‘ outlook in a report released in mid May. As of May 13, 2025, Leerink Partners has decreased its “Market perform” rating to a “an Underperform” for HALO. Earlier on October 07, 2024, Wells Fargo downgraded its rating. Their new recommendation was “an Equal weight” for HALO stock which previously was a “an Overweight”.
Analyzing HALO Stock Performance
On last trading session,, Halozyme Therapeutics Inc [NASDAQ: HALO] rose 2.49% to $58.01. The stock’s lowest price that day was $57.005, but it reached a high of $58.45 in the same session. During the last five days, there has been a surge of approximately 2.53%. Over the course of the year, Halozyme Therapeutics Inc shares have jumped approximately 9.08%. Shares of the company reached a 52-week high of $70.50 on 05/07/25 and a 52-week low of $47.50 on 05/14/25.
Support And Resistance Levels for Halozyme Therapeutics Inc (HALO)
According to the 24-hour chart, there is a support level at 57.19, which, if violated, would cause prices to drop to 56.38. In the upper region, resistance lies at 58.64. The next price resistance is at 59.27. RSI (Relative Strength Index) is 63.15 on the 14-day chart, showing neutral technical sentiment.
Is Halozyme Therapeutics Inc subject to short interest?
Stocks of Halozyme Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.37 million shares to 11.07 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 10.69 million shares. A jump of 3.39% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.1 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.1.
Which companies own the most shares of Halozyme Therapeutics Inc (HALO)?
In terms of Halozyme Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 62 in the next 12 months, up nearly 9.54% from the previous closing price of $56.6. Analysts anticipate Halozyme Therapeutics Inc stock to reach 62 by 2025, with the lowest price target being 62. In spite of this, 7 analysts ranked Halozyme Therapeutics Inc stock as Buy at the end of 2025. On September 19, 2024, JP Morgan assigned a price target of “a Neutral” to the stock and downgraded coverage with a $57.
